Suppr超能文献

[心脏移植术后一名72岁患者发生的mTOR诱导的肺炎]

[mTOR-induced pneumonitis in a 72-year-old patient after heart transplantation].

作者信息

Kasper Philipp, Göbel Heike, Michels Guido

机构信息

Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Köln.

Institut für Pathologie, Universitätsklinikum Köln.

出版信息

Dtsch Med Wochenschr. 2020 Feb;145(3):189-194. doi: 10.1055/a-1008-7206. Epub 2020 Feb 4.

Abstract

HISTORY

A 72-year-old heart transplant recipient presented to the hospital with progressive dyspnea. His immunosuppressive therapy was switched to the mTOR-inhibitor everolimus. A few months before, due to a progressive decline in renal function. Primarily, a community-acquired pneumonia was suspected and an empiric antibiotic therapy was initiated. Despite antimicrobial treatment, an acute respiratory distress syndrome developed and mechanical ventilation became necessary.

INVESTIGATIONS

During the following extensive diagnostic a transbronchial lung biopsy was performed and histological analysis revealed a drug induced lung injury.

DIAGNOSIS

Based on the clinical and histological findings an everolimus induced pneumonitis was suspected.

TREATMENT AND COURSE

The drug was immediately discontinued and a high-dose steroid treatment was started, resulting in a significant improvement of respiratory function.

CONCLUSION

Everolimus-related interstitial pneumonitis represents a rare but important adverse effect of everolimus in immunosuppressed patients. Recognition of everolimus induced pneumonitis is of high clinical relevance and should be considered in all patients on everolimus presenting with respiratory symptoms of unknown origin.

摘要

病史

一名72岁的心脏移植受者因进行性呼吸困难入院。他的免疫抑制治疗改为使用mTOR抑制剂依维莫司。几个月前,由于肾功能逐渐下降。最初怀疑是社区获得性肺炎,并开始了经验性抗生素治疗。尽管进行了抗菌治疗,但仍发展为急性呼吸窘迫综合征,需要机械通气。

检查

在接下来的广泛诊断过程中,进行了经支气管肺活检,组织学分析显示为药物性肺损伤。

诊断

根据临床和组织学检查结果,怀疑为依维莫司诱发的肺炎。

治疗及病程

立即停用该药物,并开始大剂量类固醇治疗,呼吸功能得到显著改善。

结论

依维莫司相关的间质性肺炎是依维莫司在免疫抑制患者中罕见但重要的不良反应。认识依维莫司诱发的肺炎具有高度临床相关性,对于所有出现不明原因呼吸道症状的依维莫司使用者均应考虑。

相似文献

1
[mTOR-induced pneumonitis in a 72-year-old patient after heart transplantation].
Dtsch Med Wochenschr. 2020 Feb;145(3):189-194. doi: 10.1055/a-1008-7206. Epub 2020 Feb 4.
2
Life-Threatening Everolimus-Associated Pneumonitis: A Case Report and a Review of the Literature.
Transplant Proc. 2018 Apr;50(3):933-938. doi: 10.1016/j.transproceed.2017.12.003. Epub 2018 Mar 24.
3
Early everolimus-induced pneumonitis in a renal transplant recipient: A case report.
Ann Transplant. 2012 Dec 31;17(4):144-8. doi: 10.12659/aot.883706.
4
Late Pulmonary Toxicity Associated With Everolimus in a Renal Transplant Patient and Review of the Literature.
Exp Clin Transplant. 2018 Aug;16(4):491-494. doi: 10.6002/ect.2015.0257. Epub 2016 Mar 21.
5
Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs.
Acta Radiol. 2021 Aug;62(8):1006-1015. doi: 10.1177/0284185120950100. Epub 2020 Aug 20.
6
Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Nefrologia. 2013;33(3):297-300. doi: 10.3265/Nefrologia.pre2013.Jan.11439.
7
Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
Transplant Proc. 2009 Jul-Aug;41(6):2163-5. doi: 10.1016/j.transproceed.2009.06.003.
8
Everolimus-associated pneumonitis in 3 heart transplant recipients.
J Heart Lung Transplant. 2009 Jan;28(1):104-6. doi: 10.1016/j.healun.2008.10.003. Epub 2008 Dec 12.
9
A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma.
Jpn J Clin Oncol. 2013 May;43(5):559-62. doi: 10.1093/jjco/hyt019. Epub 2013 Feb 18.
10
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
Am J Respir Crit Care Med. 2010 Aug 1;182(3):396-403. doi: 10.1164/rccm.200911-1720OC. Epub 2010 Mar 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验